Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?

We expect Merck (MRK) to beat expectations when it reports fourth-quarter and full-year 2023 results on Feb 1, before market open. In the last reported quarter, the company delivered an earnings surprise of 9.79%.Factors to ConsiderStrong global underlying demand across its business, particularly for cancer drug Keytruda and HPV vaccine Gardasil, is likely to have boosted sales growth in the fourth quarter like several previous quarters.In oncology, Keytruda sales are likely to have been driven by increased ...